BeyondSpring Inc. (BYSI)
BeyondSpring Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Florham Park, NY, US. The stock last traded at $0.76, down 0.52% on the session, giving a market capitalisation of $31.3M. On trailing twelve-month figures it carries a trailing P/E of -4.60, a net margin of 0.0%. Its beta of 0.42 implies it has historically moved less than the broad market.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
BeyondSpring Inc. is most often compared with the following Healthcare names: